Preparing Emerging Biotechs for the Best Deals


Albert Sokol predicted that the new tax law’s profits repatriation provisions and lower corporate rates mean “there will be more bio-side cash” for acquisitions and formal alliances that “sometimes energize fallow assets.” Given such innovation, he continued, “There’s no longer just one way to do stuff; there’s no longer merely the classic venture capitalists. There are now many corporate venture capital arms of pharma.”